Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Get Free Report)'s share price gapped down before the market opened on Monday . The stock had previously closed at $12.72, but opened at $12.23. Ginkgo Bioworks shares last traded at $11.85, with a volume of 209,900 shares traded.
Ginkgo Bioworks Trading Down 1.6%
The stock has a market capitalization of $653.78 million, a P/E ratio of -1.22 and a beta of 1.48. The company has a 50-day moving average price of $8.49 and a two-hundred day moving average price of $9.12.
Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.58) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. The firm had revenue of $48.32 million for the quarter, compared to analyst estimates of $38.70 million. Research analysts forecast that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current year.
Institutional Trading of Ginkgo Bioworks
Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp increased its stake in Ginkgo Bioworks by 48.2% in the 4th quarter. Bank of New York Mellon Corp now owns 23,061 shares of the company's stock valued at $226,000 after buying an additional 7,503 shares during the last quarter. SBI Securities Co. Ltd. bought a new position in shares of Ginkgo Bioworks in the fourth quarter valued at approximately $29,000. Charles Schwab Investment Management Inc. increased its position in shares of Ginkgo Bioworks by 8.0% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 233,717 shares of the company's stock valued at $2,295,000 after acquiring an additional 17,372 shares during the last quarter. SPX Gestao de Recursos Ltda bought a new stake in Ginkgo Bioworks during the fourth quarter worth $491,000. Finally, Erste Asset Management GmbH lifted its holdings in Ginkgo Bioworks by 47.9% during the fourth quarter. Erste Asset Management GmbH now owns 739,332 shares of the company's stock worth $6,979,000 after acquiring an additional 239,332 shares during the period. Hedge funds and other institutional investors own 78.63% of the company's stock.
Ginkgo Bioworks Company Profile
(
Get Free Report)
Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.
Further Reading
Before you consider Ginkgo Bioworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.
While Ginkgo Bioworks currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
